|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3 regulates both Golgi and lysosomal homeostasis and is rearranged in renal cell carcinoma (RCC), alveolar soft part sarcoma, epithelioid hemangioendothelioma, and perivascular epitheloid cell tumors (PEComas).
|
31774608 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumours showed strong nuclear immunoreactivity for TFE3.
|
30908700 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor cells were positive for TFE3 and CK.
|
28478739 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The PEComa-like tumor showed strong Melan-A and weak transcription factor E3 (TFE3) protein expression but no TFE3 gene rearrangement.
|
30876389 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All tumors showed strong nuclear immunopositivity for TFE3.
|
30920708 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No neoplasm with EWSR1-TFE3 has been reported so far, in any organ.
|
30552521 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, proposed criteria do not apply to other clinical presentations and have not been assessed in the YAP1-TFE3 positive tumors.
|
31537895 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of our study and prior studies suggest that TFE3 immunohistochemistry should play only a minor role (if any) in the diagnosis of TFE3-rearranged tumors, with fluorescence in situ hybridization representing the preferred method.
|
30851332 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, this tumour showed negative results in TFE3 and TFEB immunochemistry and split fluorescence in-situ hybridisation (FISH) assays.
|
29148086 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Both Xp11 translocation renal cell carcinomas and the corresponding mesenchymal neoplasms are characterized by a variety of gene fusions involving TFE3.
|
29713041 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IHC showed that tumor cells were diffusely positive for TFE3 and exhibited patchy and weak HMB45 staining.
|
30103811 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry results revealed tumor cell positive for TFE3, but have no consistency in carbonic anhydrase IX, CD117, Ki67, CK8/18 AE1/AE3 and so on.
|
29901594 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More than 70% of the tumor cells in the present right tumor were strongly positive for transcription factor E3 (TFE3) expression by immunohistochemical analysis with an anti-TFE3 antibody.
|
30458744 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both the primary tumor and the JU-PI cells showed nuclear expression of the TFE3 transcription factor but TFE3-activating chromosomal rearrangements were not found.
|
29788803 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica.
|
27189222 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms.
|
29212159 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation on the biopsy reveals that the tumor is positive for PAX-8, CD10, and TFE3.
|
28877071 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By immunohistochemistry, the tumor was positive for TFE3; HMB-45 stained approximately 5% of tumor cells corresponding to the histologic melanin pigment, which was confirmed with Fontana-Masson stain with bleach.
|
28877054 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear immunoreactivity for TFE3 was detected in 30 SPNs and three control tumors.
|
29272888 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In recent years, an increasing number of TFE3 rearrangement-associated tumors with melanotic features have been reported as primary neoplasm in different anatomical sites, including the kidney.
|
28208226 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical stains performed on the nephrectomy specimen showed tumor positivity for CD10, E-cadherin, a-methylacyl coenzyme A racemase, and TFE3 supporting the diagnosis of Xp11 translocation renal cell carcinoma.
|
28185421 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fluorescence in situ hybridization results showed the presence of TFE3 gene rearrangement in all four tumors, and molecular analysis revealed SDHB mutations in neoplastic cells of three tumors.
|
27910947 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the TFE3 melanotic tumor lacked any evidence of renal tubular differentiation, the TFEB melanotic cancer exhibited some staining for renal tubular markers.
|
28969862 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Malignant TFE3-rearranged perivascular epithelioid cell neoplasm (PEComa) presenting as a subcutaneous mass.
|
26385848 |
2016 |